HuMax-CD20: Phase I/II data

Data from a double-blind, dose-escalation, placebo-controlled Phase I/II study in 33 evaluable patients receiving 2 doses of IV HuMax-CD20 2 weeks apart showed that 77% of patients achieved ACR20 vs. ...